Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis~* Palpable spleen of \> 10 cm below the left subcostal margin on physical examination at the screening visit OR~* Palpable splenomegaly of 5 to 10 cm below left subcostal margin on physical exam AND active symptoms of MF at the screening visit as demonstrated by presence of 1 symptom score ≥ 5 or 2 symptom scores ≥ 3 using the Screening Symptom Form~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2~Exclusion Criteria:~* Use of experimental drug therapy for myelofibrosis, or any other standard drug (eg, danazol, hydroxyurea, etc) with the exception of ruxolitinib within 6 months of starting study (combination) therapy and/or lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better~* Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications~* Unwillingness to be transfused with blood components~* Recent history of inadequate bone marrow reserve as demonstrated by the following:~  * Platelet count \< 50 × 10\^9/L in the 4 weeks before screening or platelet transfusion(s) within 8 weeks before screening~ * Absolute neutrophil count levels \< 0.5 × 10\^9/L in the 4 weeks before screening~ * Subjects with peripheral blood blast count of \> 10% at the screening or baseline hematology assessments~ * Subjects who are not willing to receive red blood cell (RBC) transfusions to treat low hemoglobin levels~* Inadequate liver function at screening as demonstrated by the following:~  * Direct bilirubin ≥ 2.0 × the upper limit of laboratory normal (ULN). (NOTE: direct bilirubin will only be determined if total bilirubin is ≥ 2.0 × ULN)~ * alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.5 × ULN~* Inadequate renal function at screening as demonstrated by creatinine clearance \< 50 mL/min or glomerular filtration rate \< 50 mL/min/1.73 m\^2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Ruxolitinib + Parsaclisib (Type: EXPERIMENTAL): Initial cohort dose of parsaclisib added to existing stable regimen of ruxolitinib, with subsequent cohort escalations based on protocol-specific criteria.
- Part 2: Ruxolitinib + Parsaclisib (Type: EXPERIMENTAL): Part 2 will compare 2 doses of parsaclisib .
- Part 3: Ruxolitinib + Parsaclisib (Type: EXPERIMENTAL): Part 3 will compare 2 different long term dosing strategies.
- Part 4: Ruxolitinib + Parsaclisib (Type: EXPERIMENTAL): Part 4 will compare 2 different daily dosing strategies.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues